Boehringer Ingelheim adds blue internal teat sealant to its dairy mastitis portfolio
- Boehringer Ingelheim continues to stay at the forefront of innovation and provide producers with the right tools for disease prevention
- The Company’s Ubroseal® Blue brings confidence of best practice when it comes to sealant administration and removal
Ingelheim, Germany, April 15, 2021 – Boehringer Ingelheim, a global leader in animal health, announces that it has updated its Ubroseal® internal teat sealant to Ubroseal® Blue earlier this year. Ubroseal® Blue will be available in selected countries worldwide as part of the Company’s mastitis portfolio.
Ubroseal® Blue joins Ubrostar® and Bovikalc® Dry as part of the Boehringer Ingelheim Animal Health’s dry cow management portfolio to prevent new intramammary infections during the dry period. It provides the easiest and most hygienic application and the only one to feature a visible blue color that is easy to distinguish from milk during removal.
“The blue paste is a powerful differentiator,” shared Dr. Gerald Behrens, Global Head of Ruminants at Boehringer Ingelheim Animal Health. “The addition of a blue color to Ubroseal® is a unique and exclusive feature that enhances farmers’ dry cow management practices. As it’s easier to distinguish the sealant from milk, producers no longer have to worry about unnecessarily sending a cow to the hospital pen.”
Twenty-five percent of quarters remain open one week after dry-off, creating an opportunity for infection to occur.1 Using teat sealants is a very effective way to reduce the risk of new infection during the dry period.
To learn how to incorporate Ubroseal® Blue into your herd’s mastitis protocol, talk to your veterinarian or Boehringer Ingelheim representative or visit www.ubroseal.com in order to learn more.
Boehringer Ingelheim Animal Health
The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 10,000 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.
Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.
Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of 4.1 billion euros in 2020 and presence in more than 150 countries. For more information visit: www.boehringer-ingelheim.com/animal-health/overview.
Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
1Ruegg P. - Managing the dry period for quality, 2011